Dynavax Technologies | Des Atouts



Assets Changement Date
AbbVie USD 135.16B 8.26B 2024-12
Adma Biologics USD 488.68M 98.06M 2024-12
Amgen USD 91.84B 956M 2024-12
AstraZeneca USD 104.04B 887M 2024-12
Biogen USD 28.05B 263.9M 2024-12
BioMarin Pharmaceutical USD 6.99B 137.74M 2024-12
Bristol-Myers Squibb USD 92.6B 1.07B 2024-12
Dynavax Technologies USD 986.26M 75.73M 2024-12
Gilead Sciences USD 59B 4.47B 2024-12
Glaxosmithkline GBP 59.46B 1.41B 2024-12
Merck USD 117.11B 426M 2024-12
Neurocrine Biosciences USD 3.72B 183.7M 2024-12
Novartis USD 102.25B 1.28B 2024-12
Pfizer USD 213.4B 6.08B 2024-12
Regeneron Pharmaceuticals USD 37.76B 317.5M 2024-12
Roche Holding CHF 101.8B 6.02B 2024-12
Sarepta Therapeutics USD 3.96B 363.24M 2024-12
TG Therapeutics USD 577.69M 8.32M 2024-12
Vertex Pharmaceuticals USD 22.53B 293M 2024-12



Dynavax Technologies Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Apr 2025.